Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care

Journal of Internal Medicine

Volumn 243, Issue 5, 1998, Pages 373-380

  Eriksson, M ^a   Hadell K ^a   Holme, I ^b   Walldius, G ^c   Kjellstrom T ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholesterol; Cholestyramine; Compliance; Lipid lowering; Pravastatin; Primary care; Sex

Indexed keywords

ANTILIPEMIC AGENT; COLESTYRAMINE; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTYRAMINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRAVASTATIN; PRIMARY HEALTH CARE; SEX FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 0031859105     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00294.x     Document Type: Article

References (19)

1. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV. Hoen H et al. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419-25.
2. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramin alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993; 153: 1321-9.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916-24.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
7. EAS. Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines: Nutr Metab Cardiovasc Dis 1992; 2: 113-56.
8. Treatment of hyperlipidemia., Information from Swedish Med Products Agency 1995; 3: 178-87, S-75103, Uppsala. Sweden.
9. Urquhart J. Patient compliance as an explanatory variable in four cardiovascular studies. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press, 1991: 301-22.
10. Walldius G, Erikson U, Olson AG, Bergstrand L, Hädell K, Johansson J et al. The effect of probucol on femoral atherosclerosis: The Probucol Qantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 875-83.
11. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31.
12. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 241: 317-25.
13. Information from the Department of Drugs. Swedish Natl Board Health Welfare 1988; 13: 152-65. S-106 30 Stockholm. Sweden.
14. National Food Administration. Swedish Nutrition Recommendations (SNR) 2nd edn, June 1989. S-75126, Uppsala, Sweden.
15. Study Group European Atherosclerosis Society. Strategy for prevention of coronary heart disease. A policy statement of the European Atherosclerosis Society. Eur Heart J 1987; 8: 77-88.
16. ICD-9. International Classification of Diseases, WHO, 1987. Geneva.
17. Warmick GR, Binderson J, Albers JJ. Dextran-sulphate - Mg2 + precipitation procedure for quantitation of high density lipoprotein cholesterol. Selected methods Clin Chem 1983; 10: 91-100.
18. Friedewald WT, Levy I, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Swedish Drug Statistics 1995 National Board of Swedish Pharmacies. S-106 30 Stockholm, Sweden.